deferasirox has been researched along with Blood Diseases in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blinder, M; Bobbili, P; Cheng, WY; Duh, MS; Hao, Y; Nandal, S; Said, Q; Vekeman, F; Xiao, Y | 1 |
| Albrecht, S; Geer, T; Hebart, H; Hofmann, WK; Jarisch, A; Johr, C; Nolte, F; Nückel, H; Rubanov, O; Schmidt, B; Schumann, C | 1 |
| Bruederle, A; Han, J; Porter, JB; Taher, AT; Weber, S | 1 |
| Cid, J; Díaz, M; Palomera, L; Solano, F; Zamora, C | 1 |
| Kontoghiorghes, GJ | 1 |
| Chirnomas, D; Esposito, J; Giardina, PJ; Goldberg, SL; Paley, C; Vichinsky, E | 1 |
| Al Zoebie, A; Bruederle, A; Chotsampancharoen, T; El-Beshlawy, A; Elalfy, M; Gilotti, G; Han, J; Kamdem, A; Koussa, S; Vichinsky, E | 1 |
| Cappellini, MD; Porter, JB; Taher, AT; Vichinsky, EP | 1 |
| Brown, GC; Patton, WN; St Pierre, TG; Tapp, HE; Taylor, DJ | 1 |
| Cappellini, MD; Hoffbrand, AV; Taher, A | 1 |
| Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT | 1 |
| Stumpf, JL | 1 |
| Maggio, A | 1 |
| Vichinsky, E | 1 |
| Hampton, T | 1 |
3 review(s) available for deferasirox and Blood Diseases
| Article | Year |
|---|---|
Deferasirox.
Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Patient Compliance; Siderophores; Transfusion Reaction; Triazoles | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles | 2007 |
Clinical application of deferasirox: practical patient management.
Topics: Administration, Oral; Adult; Benzoates; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Contraindications; Creatinine; Deferasirox; Disease Management; Drug Eruptions; Gastrointestinal Diseases; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Transfusion Reaction; Triazoles | 2008 |
1 trial(s) available for deferasirox and Blood Diseases
| Article | Year |
|---|---|
The palatability and tolerability of deferasirox taken with different beverages or foods.
Topics: Adolescent; Benzoates; Beverages; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Food; Food-Drug Interactions; Hematologic Diseases; Hemosiderosis; Humans; Iron Chelating Agents; Male; Triazoles | 2013 |
11 other study(ies) available for deferasirox and Blood Diseases
| Article | Year |
|---|---|
Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Topics: Adult; Chelation Therapy; Deferasirox; Dosage Forms; Drug Substitution; Female; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Medicare; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; United States | 2018 |
Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Deferasirox; Erythrocyte Transfusion; Female; Germany; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Young Adult | 2018 |
Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.
Topics: Adolescent; Adult; Blood Transfusion; Child; Clinical Trials, Phase II as Topic; Deferasirox; Double-Blind Method; Female; Ferritins; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Models, Biological; Multicenter Studies as Topic; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Tablets; Young Adult | 2019 |
Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.
Topics: Aged; Benzoates; Chelation Therapy; Comorbidity; Deferasirox; Disease Management; Erythrocyte Transfusion; Female; Ferritins; Guideline Adherence; Hematologic Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Practice Guidelines as Topic; Spain; Transfusion Reaction; Triazoles | 2014 |
Turning a blind eye to deferasirox's toxicity?
Topics: Age Factors; Benzoates; Cause of Death; Chronic Disease; Deferasirox; Drug Approval; Europe; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2013 |
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
Topics: Benzoates; Chelation Therapy; Child, Preschool; Deferasirox; Female; Hematologic Diseases; Hemosiderosis; Humans; Iron Chelating Agents; Male; Transfusion Reaction; Triazoles | 2017 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Iron Chelating Agents; Pyridones; Risk Assessment; Siderophores; Triazoles | 2008 |
Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
Topics: Adolescent; Adult; Aged; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Hematologic Diseases; Hemosiderosis; Humans; Infant; Infusions, Intravenous; Injections, Subcutaneous; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Retrospective Studies; ROC Curve; Sensitivity and Specificity; South Australia; Triazoles | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2012 |
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Strides made in red blood cell disorders, but substantial barriers to care remain.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzoates; Brain Diseases; Chelation Therapy; Deferasirox; Hematologic Diseases; Hematology; Humans; Hydroxyurea; Iron Chelating Agents; Triazoles | 2008 |